Sanofi Consumer Healthcare India Limited (SANOFICONR) Q3 2024 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended September 30, 2024, following a major demerger and listing event.

• Financials reflect the demerger of the Consumer Healthcare business from the parent entity, with results not directly comparable to prior periods.

Financial highlights

• Revenue from operations for Q3 2024 was ₹1,599 million; nine months ended September 2024 was ₹5,355 million.

• Profit before tax for Q3 2024 was ₹1,017 million; for nine months, ₹3,340 million.

• Net profit for Q3 2024 was ₹450 million; for nine months, ₹1,367 million.

• Basic and diluted EPS for Q3 2024 was ₹19.54; for nine months, ₹59.36.

Outlook and guidance

• Results for Q3 2024 are not comparable with Q2 2024 due to seasonality, voluntary product recall, and pending market authorizations.

• Non-recalled product portfolio continues to perform strongly.